hotspot -WSS

hotspot

author：focus 2025-09-14 11:44:06 - browse：2

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： A new study asks: Are we harming blood donors by taking blood?

entertainment

WSS

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Bird flu in dairy cattle: New measures to control spread to humans

Brain 'hot spot' may explain why African Americans feel greater pain

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Young boy dies in trial for Pfizer Duchenne gene therapy

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Affirmative action in medical school literally saved lives

Hundreds died while taking an arthritis drug, but nobody alerted patients

State Dept. review finds Biden bears some blame for Afghanistan failures

Listen: Biogen's messy board & Laronde's data problem

State Dept. review finds Biden bears some blame for Afghanistan failures

Four alarming medical procedures we’re glad history forgot

Virginia high school admissions case could be legal follow

Covid silver lining: Unprecedented look at human immune system

Apple is now the first public company to be valued at $3 trillion

Brain 'hot spot' may explain why African Americans feel greater pain

knowledge

7 people shot in DC, police say

New case study details death in closely watched Alzhiemer's trial

Harvard scientists, with Google, unveil the most detailed brain map ever

Covid silver lining: Unprecedented look at human immune system

Young boy dies in trial for Pfizer Duchenne gene therapy

Listen: Biogen's messy board & Laronde's data problem

entertainment

leisure time

entertainment

focus